Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
2019 · The Lancet · 600 citations
https://doi.org/10.1016/s0140-6736(19)31150-x
J
Jennifer A. Marks
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
48
Papers
5.8K
Citations
14
h-index
17
i10-index
Jennifer A. Marks is an academic researcher from Dana-Farber Cancer Institute. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Diabetes Management and Research & Diabetes Treatment and Management. The author has an h-index of 14, co-authored 41 publications.
ORCID: 0000-0002-8592-9892Papers by this author
worksNivolumab-associated cutaneous T-cell lymphoma
2021 · JAAD Case Reports · 7 citations
https://doi.org/10.1016/j.jdcr.2020.12.033
PP01.14 Paired Sample Analyses of NSCLC After SCLC Transformation
2025 · Journal of Thoracic Oncology · 0 citations
https://doi.org/10.1016/j.jtho.2025.03.021
P3.01.18 The Journey to a Lung Cancer Diagnosis: Reports From the LEAD Study
2025 · Journal of Thoracic Oncology · 0 citations
https://doi.org/10.1016/j.jtho.2025.09.764
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat